Immune Design Corp (IMDZ.OQ)
3.65USD
19 Apr 2018
$-0.22 (-5.81%)
$3.88
$3.85
$3.85
$3.65
24,531
77,446
$13.00
$2.80
About
Overall
| Beta: | -- |
| Market Cap(Mil.): | $269.01 |
| Shares Outstanding(Mil.): | 25.62 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| IMDZ.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -2.20 | -- | -- |
| ROI: | -66.38 | 1.58 | 14.38 |
| ROE: | -66.44 | 2.41 | 16.07 |
BRIEF-Immune Design Reports Q4 Loss Per Share $0.29
* IMMUNE DESIGN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Immune Design Reports Data Update For Lead Immunotherapy Programs
* IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA
BRIEF-Immune Design To Report Q4 And Year End 2017 Financial Results And Provide Corporate Update
* IMMUNE DESIGN TO REPORT FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:
BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design
* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing Source text: (http://bit.ly/2zkI4Ki) Further company coverage:
BRIEF-Immune Design reports Q3 loss per share of $0.52
* IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Immune Design prices offering of 19.5 million shares at $4.10 per share
* Immune Design prices $80.0 million public offering of common stock
BRIEF-Immune Design proposes public offering of common stock
* Immune Design announces proposed public offering of common stock
Estimates